AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04605900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education on foot self-care
Description: An information leaflet with foot care was delivered, with the aim of ensuring that participants were informed about the care they should continually take with their feet during the study period. This leaflet was created based on the guidelines of the Associação Protetora dos Diabéticos in Portugal.
Study NCT01270035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: To increase the ADA dose from 40 mg eow to 80 mg eow
Study NCT02505958 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: high caloric intake
Description: Volunteers will be started on a diet program for 4 ½ days, consisting of 3 meals and 3 snacks over a 24 hour period and containing \~ 6000 Kcal/24 h.
Study NCT02505958 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: reduced caloric intake
Description: On days 5 and 6, volunteers will received 3 meals (\~333 calories each) totaling \~ 1,000 calories/24 hours.
Study NCT04773223 — intervention group
Intervention type: PROCEDURE
Intervention: Open surgery and complex EVAR due to AAA
Description: There will be two cohorts:~1. Patient undergoing open surgery~2. Patients undergoing complex endovascular repair (fenestrated, chimney, etc.)
Study NCT03259958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil TDS
Description: Donepezil Hydrochloride Transdermal Delivery System
Study NCT03259958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept
Description: Aricept Tablet
Study NCT01819714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-sensory supportive care
Description: The Serre-Cavalier center will implement Snoezelen-type multisensory care sessions for included patients; these care sessions correspond with the patients' daily hygiene/toilette care.~The impact of this multisensory strategy will be evaluated using a before-after design.
Study NCT04768140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bobath treatment approach
Description: scapulothoracic mobilization exercise, reaching in different directions in the supine position and upper extremity weight transfer exercise.
Study NCT04768140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: range of motion, stretching, strengthening exercises, electrotherapy, thermotherapy, balance and mobility exercises and exercises for daily living activities.
Study NCT04768140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: range of motion, stretching, strengthening exercises, electrotherapy, thermotherapy, balance and mobility exercises and exercises for daily living activities.
Study NCT04685993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPCN 1144
Description: Oral LPCN 1144, total daily dose of 450 mg testosterone undecanoate administered as BID (225 mg testosterone undecanoate per dose).
Study NCT01065818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoro-L-Thymidine
Description: 4D-PET/CT imaging with an injection of Fluoro-L-Thymidine at pre-Neoadjuvant Therapy and post-3 weeks Neoadjuvant Therapy prior to surgery.
Study NCT04387123 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginoscopy
Description: Vaginoscopic examination and possible operative endoscopic management
Study NCT01447407 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-3 vaccine with alum IM
Description: One dose administered IM
Study NCT01447407 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-3 vaccine without alum IM
Description: One dose administered IM
Study NCT01447407 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with alum IM
Description: One dose administered ID
Study NCT01447407 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-3 vaccine without alum ID
Description: One dose administered ID
Study NCT02420535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediately Receive Tool
Study NCT02420535 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One Month Delay
Study NCT02464124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: • Nitazoxanide dosing: 500 mg tablets twice daily
Study NCT02464124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: • Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day
Study NCT02464124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: • Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day
Study NCT04023396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: ABX464~All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks.
Study NCT03388424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: quantification of microbiota
Description: For each group a sample of biological sample will be take and will be analyzed using the n-counter flex platform in order to quantify disbiosis
Study NCT04811157 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test product
Description: 200 g/day of unsweetened yogurt supplemented with a dietary fiber blend
Study NCT04811157 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control product
Description: 200 g/day of unsweetened yogurt
Study NCT02412124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Complete W2W mentoring program
Study NCT02412124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Complete the FACT-G
Study NCT02412124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete the W2W Patient Survey
Study NCT02739217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4050
Description: Four 200 mg capsules (800 mg total) administered orally, once daily.
Study NCT02515630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMB
Description: Momelotinib (MMB) tablet administered orally once daily
Study NCT04542980 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV2 Autoantibody detection
Description: Through the data collected from this study we hope to support the development of an ELISA assay for the detection of IgM and IgG autoantibodies produced in response to the presence of SARS-CoV2
Study NCT03092752 — intervention group
Intervention type: DRUG
Intervention: oral antidiabetic drugs
Description: OADs usage conditions and dose selection in T2DM patients
Study NCT02311829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone follow-up device
Description: For patients in the DST group only: Phone calls by clinical psychologist at J 15 at 2, then every 2 months until M12.
Study NCT02646969 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Formula regimen 1
Study NCT02646969 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Formula regimen 2
Study NCT00488423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mixed Meal Tolerance test, Hyperglycemic clamp
Description: Subjects undergo a standard mixed meal tolerance test \& hyperglycemic clamp to assess insulin secretion \& sensitivity (whole body glucose disposal) pre-op. Following surgery, at 1week, 1 month, 6 months and 12 months subjects will undergo hyperglycemic clamp \& mixed meal tolerance test. During these tests, measurements will include plasma levels of glucose, insulin, C-peptide, free fatty acid levels and adipocyte hormone profile (adiponectin, leptin, resistin). A gut hormone profile (ghrelin, glucagons-like-peptide 1 GLP-1, glucose-dependent insulinotropic polypeptide GIP, PYY) will be performed at fasting \& specific postprandial times. Results will be compared between two groups: patients undergoing laparoscopic Roux-en-Y gastric bypass \& gastric banding.
Study NCT01769677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).
Description: Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
Study NCT04064112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: S-BLR
Description: Surgery of slanted bilateral LR recession for CI-IXT patients
Study NCT04064112 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: C-BLR
Description: Surgery of conventional bilateral lateral rectus recession for CI-IXT patients
Study NCT04073719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apple Cider Vinegar
Description: Will drinking apple cider vinegar increase urinary citrate levels to a greater degree than other beverages and which beverages produce the most significant effects compared against one another.
Study NCT03778554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate
Description: Eligible patients randomized to receive long-term therapy with oral beta-blockade
Study NCT03778554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Eligible patients randomized to receive long-term therapy with oral beta-blockade
Study NCT03778554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Eligible patients randomized to receive long-term therapy with oral beta-blockade
Study NCT03778554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Eligible patients randomized to receive long-term therapy with oral beta-blockade
Study NCT04073719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Other Beverage
Description: To what degree do other high citrate beverages impact urinary citrate output.
Study NCT00412841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 40mg vs placebo 40mg daily
Study NCT00412841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI, Venipuncture
Description: MRIs done baseline, four and nine months
Study NCT00412841 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: MRI, Venipuncture
Description: MRIs done baseline, four and nine months
Study NCT00412841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets identical to atorvastatin 40mg
Study NCT01015326 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Administered questionnaire
Study NCT04702152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted memory reactivation (sounds)
Description: I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be non-congruently related to the scenes in the previous learning task. This manipulation is within-subject - all participants will get it, but different specific sounds will be presented for each individual participant.
Study NCT03262077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Irradiation with low-level laser for 1, 3, and 5 min
Study NCT03262077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue Oral Product
Description: Irradiation with low-level laser for 1, 3, and 5 min
Study NCT00941850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upgrade to triple ventricular site CRT
Description: Patients in this arm will continue to receive CRT via the original unit, but some will have a change in the mode of delivery of therapy (by placing a second pacing lead to reach a different part of the left ventricle from the part originally paced).
Study NCT03583658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ambroxol BIH1526
Description: Pharmaceutical form: lozenges Route of administration: oromucosal
Study NCT03583658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: lozenges Route of administration: oromucosal
Study NCT02433847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride
Study NCT02702089 — intervention group
Intervention type: PROCEDURE
Intervention: Rectal cancer surgery
Description: Rectal cancer resection
Study NCT01586052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: 250 IU/kg, Twice a week for 4 weeks
Study NCT00752089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaF/ KNO3/isopentane Dentifrice
Description: Experimental toothpaste
Study NCT00752089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaF/KNO3 Dentifrice
Description: Experimental toothpaste
Study NCT00752089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaF Dentifrice
Description: Active comparator
Study NCT00752089 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dentifrice
Description: Placebo comparator
Study NCT02025192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Administered twice per day, orally.
Study NCT02025192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m\^2 administered twice per day, orally in Days 1-14 of each 21-day cycle.
Study NCT02025192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
Study NCT03087734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of new model of bar with oblique stabilizers
Description: Implantation of new model of bar with oblique stabilizers
Study NCT03087734 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of regular bar with perpendicular stabilizers
Description: Implantation of regular bar with perpendicular stabilizers
Study NCT03200548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxing acupressure plus usual care
Description: Experimental group. Self-administered acupressure is one possible safe, self-management technique for which may be effective for improving fatigue as well as physical and psychosocial functioning in several chronic disease populations. Acupressure, a technique derived from acupuncture, is a component of Traditional Chinese Medicine (TCM) in which pressure is applied to specific acupoints on the body using a finger or small device, to treat disease.
Study NCT03200548 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Negative control group. Participants are asked to carry on with their usual management practices and habits.
Study NCT03200548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulating acupressure plus usual care
Description: Experimental group. Self-administered acupressure is one possible safe, self-management technique for which may be effective for improving fatigue as well as physical and psychosocial functioning in several chronic disease populations. Acupressure, a technique derived from acupuncture, is a component of Traditional Chinese Medicine (TCM) in which pressure is applied to specific acupoints on the body using a finger or small device, to treat disease.
Study NCT03200548 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham acupressure plus usual care
Description: Positive control group. Chosen pressure points are not known to be effective.
Study NCT03228641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: micro-excisional skin removal with coring needle
Study NCT03098680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate
Description: see arm/group descriptions
Study NCT03098680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicardipine Hydrochloride
Description: see arm/group descriptions
Study NCT03098680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine Hydrochloride
Description: see arm/group descriptions
Study NCT03098680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine Hydrochloride
Description: see arm/group descriptions
Study NCT03098680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil Hydrochloride
Description: see arm/group descriptions
Study NCT03098680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Mesylate
Description: see arm/group descriptions
Study NCT03098680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: see arm/group descriptions
Study NCT02177929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adapted canoeing, hadbike and conventional physiotherapy
Description: The subjects adapted canoeing group will practice on the kayak and rowing exercises associating with ball.~The individuals in the group will handbike workouts outdoors and surpassing cirucuitos mounted with cones.~Individuals in the conventional physiotherapy group will make stretching and strengthening exercises.
Study NCT00716456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib with cetuximab
Description: The phase I portion will accrue as many as 3 cohorts of 3-6 patients; receiving erlotinib 100 mg daily along with escalating doses of cetuximab administered every 2 weeks beginning at 250mg/m2 IV without a loading dose. Subsequent cetuximab dose levels will be 375 mg/m2, and 500 mg/m2, administered IV every 2 weeks. Patients will have baseline CT, labs and ECG done within 2 weeks of study entry. Three patients will be enrolled per dose level. Patients will be monitored for toxicity weekly for the first 5 weeks, and every 2 weeks thereafter. Patients will be monitored for response by CT in the fourth week of combined therapy and every 8 weeks. All patients in this portion of the trial will receive intravenous cetuximab every two weeks at the MTD (to be determined in phase I portion) and daily erlotinib on an outpatient basis and will obtain clinical re-evaluation and radiographic re-imaging on a schedule similar to that followed in the phase I portion
Study NCT03123081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking
Description: At birth the cord of a depressed newborn is clamped immediately and cut 30 cm from the umbilicus. After completion of initial steps, if required, positive pressure ventilation (PPV) is given for 30 seconds, along with UCM. The cord is untwisted and held in a vertical position. It is milked 3 times towards the baby at a speed of 10 cm/s and then clamped 3 cm from the umbilicus. After completion of PPV along with UCM, if the baby requires further resuscitation, the NRP 2015 guidelines will be followed. Depressed newborns who respond to initial steps of resuscitation with normal breathing and heart rate of 100 bpm or higher, will receive UCM after this.
Study NCT03545945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional office hysteroscopy
Description: Patients in the study arm will undergo diagnostic office hysteroscopy where they look for any underlying polyp, fibroids or uterine anomaly in addition to endometrial biopsy.
Study NCT03545945 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endometrial biopsy
Description: Patients randomized to endometrial biopsy only group will be prepped with betadine solution and local anesthesia in the form of lidocaine gel placed in the external cervical canal and biopsy will be performed using a Pipelle catheter.
Study NCT03545945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Description: Patients randomized to endometrial biopsy only group will be prepped with betadine solution and local anesthesia in the form of lidocaine gel placed in the external cervical canal and biopsy will be performed using a Pipelle catheter.
Study NCT02294279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qvar (100 mcg)
Description: 2 puffs twice daily; 400 mcg daily over 4 weeks treatment period
Study NCT03006237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IS-001
Description: 10mg, 20mg or 40 mg IV IS-001 drug administered during surgery
Study NCT03006237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci® Si/Xi Surgical System
Description: robot-assisted minimally invasive hysterectomy surgery performed with da Vinci® Si/Xi Surgical System with Firefly® Fluorescent Imaging